Please login to the form below

Not currently logged in
Email:
Password:

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

AZ, Amgen’ s first-in-class asthma drug gets breakthrough status. The IL-5 inhibitor is already approved for severe asthma in the EU. ... Regeneron’s new candidate Dupixent (dupilumab), an IL-4 and IL-13 inhibitor that is already approved for atopic

Latest news

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab)

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    Nucala was the first IL-5 inhibitor to reach the market in 2015, and made £344m ($465m) in sales last year. ... IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic

  • NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

    Despite the confidential discount on Dupixent’s list price of £1, 264.89 per pack of two syringes of the IL-4 and IL-13 inhibitor - developed with Regeneron - the cost

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AstraZeneca has picked up an approval in the EU for its interleukin-5 inhibitor Fasenra in severe asthma, mirroring its US approval in this indication last November. ... Prospects for IL-13 inhibitor tralokinumab look terminal after three failed

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    The US FDA has approved AstraZeneca’s interleukin-5 inhibitor Fasenra for severe asthma, setting up a fight in the market with rival drugs from GlaxoSmithKline and Teva. ... Prospects for IL-13 inhibitor tralokinumab look rocky after two failed

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics